Voiding and Erectile Function After Retroperitoneal Lymph Node Dissection for Testicular Cancer

Recruiting Observational Study
Testicular Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Male
Study type
Observational
Participants needed
20 (estimated)
Sponsor
Jagiellonian University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study aims to evaluate how retroperitoneal lymph node dissection (RPLND), a surgical treatment for testicular cancer, may affect urinary and sexual functions in men. RPLND involves the removal of lymph nodes from the abdominal area and is sometimes necessary in patients who are not eligible for chemotherapy or who have residual disease after chemotherapy. While this surgery is known to carry …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adult male with testicular cancer undergoing retroperitoneal lymph node dissection (RPLND) Exclusion Criteria: * History of RPLND * Lack of consent
Contacts

Anna K. Czech, M.D., Ph.D.

+48124002500

aka.czech@uj.edu.pl

CONTACT

Jakub Frydrych, M.D.

+48124002500

frydrych.jf@gmail.com

CONTACT